Valuation & Positioning

PharmaVentures uses proven valuation techniques, methodologies and components to value companies, assets and licensing deals.

Our valuations are typically used for internal, external and statutory purposes in support of funding rounds, licensing deals, acquisitions and asset sales.

We have valued assets across a wide range of different therapy areas such as CNS, Ophthalmology, Oncology, GI and Respiratory diseases. A number of major pharmaceutical companies have also relied upon our valuations for determining the outcome of a number of high-profile contractual disputes.

Dedicated Advisors

Adrian Dawkes
Managing Director
Phone: +44 (0) 7931 428 487
adrian@pharmaventures.com

Stephen Waterman
Managing Director
Phone: +44 (0) 7931 144 097
steve@pharmaventures.com

Kate Moore
Vice President
Phone: +44 (0)7960 508 429
kate@pharmaventures.com

Expertise and Knowledge

Top tier pharmaceutical and biotech companies, spin outs and start-ups have trusted us to provide expert valuation and deal structuring services to help them understand the real value of their assets and companies.

  • Experience valuing companies including pharmaceutical, biotech, diagnostics, medical devices, contract research and manufacturing, and specialty pharmaceutical
  • Independent valuation expertise in the demanding environments of global litigation and arbitration cases
  • Classic valuation methodologies such as discounted cash flow (DCF), net present value (NPV) and Monte Carlo simulations with deal comparables and innovative in-house approaches, which form a proven and comprehensive suite of valuation tools

 

 

Our Case Studies

Life Sciences Valuation

A large diversified chemical company made a strategic decision to potentially divest one of its pharmaceutical related business units that lay outside its core strengths. In order to understand the potential sales returns and to develop a sales strategy, it needed to provide a life sciences valuation of the complex business.

Market Sizing & Forecasting

A Research & Development company was approaching the end of Phase II trials with a re-formulated compound. Although the company had confidence over their forecasts for the US, they lacked an understanding of the more complex European and Asian markets. 

The Pharma Product/ Technology/ Company Valuation

A US specialist drug delivery company needed urgently to get a valuation of a potential acquisition candidate company. With its delivery technology the candidate company held a strong IP position in an undeveloped but emerging market area.

How can we help you?

We deliver robust, comprehensive, real world valuations and deal structures to address all likely scenarios.

Z
Asset and company valuations
Z
Independent valuation reports
Z
Predictive valuation models
Z
Interactive spreadsheets for use in negotiations
Z
Deal structuring and term sheet analysis
Z
Market opportunity assessments (KOL validated)
Z
Market positioning
Z
Market driven benchmarking

All FCA regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited is a wholly owned subsidiary of Pharma Ventures Ltd. Past performance is not a guarantee of future performance. Information contained herein is for illustrative purposes only and should not be relied upon.

Our White Papers

How to Interpret and Negotiate Deal Terms for a Life Science Licensing Agreement

This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development.